Androgen Support and Erectile Function in Men with Diabetes Mellitus Type 2 and Obesity


В. Є. Лучицький


The objective: to study to determine state of erectile function and androgen support in men with diabetes mellitus type 2 and obesity.

Materials and methods. A total of 56 men aged 35 to 65 years old were examined from CD2 (38 with obesity (group I) and 18 without obesity (group II)) and 82 healthy men who formed a control group. In blood, the concentration of follytropin (FSH), lutropin (LH), total testosterone (Ttot), testosterone free (Tfree), estradiol (E2), sex steroid binding globulin (SSBH) and prolactin (PRL) were determined by immunoferment method. The obesity criterion was considered as body mass index (BMI) >30 kg/m2. The state of erectile function was investigated using the International Index of Erectile Function Questionnaire (IIEF-15).

Results. The average blood serum levesl of Ttot and Tfree in both groups of patients were lower thsn in the control group. The average levels of estradiol in blood of , Group I patients were significantly higher compared to patients in Group ІІ. The average levels of pituitary hormones: FSH, LH and PRL in the patients of both examined groups were not significantly different from those in control group. The results of MIEF-15 inmen with type 2 diabetes and androgen deficiency revealed a marked decrease in all indicators of erectile function in the examined groups compared with the control ones. A more pronounced decrease in integrative indexes of MIEF-15 questionnair were in the subjects with obesity.

Conclusions. The obtained data (reduction of erectile function, orgasm, libido) indicate the presence of a violation of the hormonal component of the regulation of the sexual function in men with type 2 diabetes and obesity.


How to Cite
Лучицький, В. Є. (2018). Androgen Support and Erectile Function in Men with Diabetes Mellitus Type 2 and Obesity. Health of Man, (4), 76–80.
Sexology and andrology
Author Biography

В. Є. Лучицький, The State Institution «V.P. Komisarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine»

Vitalii Ye. Luchitsky,

Department of Gonadal Pathology, Division of Clinical Andrology


Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity / D. Kapoor, H. Aldred, S. Clark [et al] // Diabetes Care. – 2007. – Vol. 30. – P. 911–917.

The association of body mass index with the risk of type 2 diabetes: a case control study nested in an electronic health records system in the United States / M. Ganz, N. Wintfeld, Q. Li [et al.] // Diabetol.& Metabolic Syndr. – 2014. – Vol. 6. – P. 50.

Grossmann M. Testosterone and type 2 diabetes / M. Grossmann, E.J. Gianatti, J.D. Zajac // Curr. Opin. Endocrinol. Diabetes Obes. – 2010. – Vol. 17, N 3. – P. 247–256.

The relative contributions of aging, health and lifestyle factors to serum testosterone decline in men / T.G. Travison, A.B. Araujo, V. Kupelian [et al.] // J. Clin. Endocrinol.Metab. – 2007. – Vol. 92. – P. 549–555.

Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania / R. Haring, T. Ittermann, H. Volzke [et al.] // Aging Male. – 2010. – Vol. 13. – P. 247–257.

Ruige J.B. Does low testosterone affect adaptive properties of adipose tissue in obese men? / J.B. Ruige // Arch. Physiol. Biochem. – 2011. – Vol. 117, N 1. – P. 18–22.

Larsen S.H. Sexual function and obesity (Lond) / S.H. Larsen, G. Wagner, B.L. Heitmann // Int J Obes (Lond). – 2007. – Vol. 1. – P. 1189–1198.

Decreased androgen levels in massively obese men may be associated with impaired function of gonadostat / N. Lima, H. Cavaliere, M. Knobel [et al.] // Int. J. Obes. Relat. Metab. Disord. – 2000. – Vol. 24(11). – P. 133–137.

Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism obese men / A. Vermeulen, J.M. Kaufman, J.R. Deslypere [et al.] // J. Clin. Endocrinol. Metab. – 1993. – Vol. 76. – P. 1140–1166.

Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity / D. Kapoor, H. Aldred, S. Clark [et al] // Diabetes Care. – 2007. – Vol. 30. – P. 911–917.

Low testosterone levels are common and associated with insulin resistance in men with diabetes / M. Grossmann, M.C. Thomas, S. Panagiotopoulos [et al.] // J. Clin. Endocrin. Metab. – 2008. – Vol. 93. – P. 1834–1840.

Estradiol in elderly men / А. Vermeulen, J.M. Kaufman, S. Goemaere, I. van Pottelberg // Aging Male. – 2002. – Vol. 5. – P. 98–102.

Low estradiol Concentrations in men With Subnormal Testosterone Concentrations and Type 2 Diabetes / S. Dhindsa, R. Furlanetto, M. Vora [et al.] // Diabetes Care. – 2011. – Vol. 34. – P. 1854–1859.

EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study / A. Tajar, G. Forti, T.W. O‘Neil [et al.] // J. Clin. Endocrin. Metab. – 2010. – Vol. 95. – P. 1810–1818.

Insulin-dependent diabetes in men is associated with hypothalamo-pituitary derangement and with impairment in semen quality / B. Baccetti, La Marca, P. Piomboni [et al.] // Hum. Reprod. –2002. – Vol. 17, N 10. – P. 2673–2677.

Testosterone and metabolic syndrome: a meta-analytic study / G. Corona, M. Monami, G. Ratsrelli [ et al.] // J. Sex. Med. – 2011. – Vol. 8. – P. 272–283.

Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment / I. Huhtaniemi // Asia J.Androl. – 2014. – Vol. 16. – P. 192–202.

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes / D. Kapoor, E. Goodwin, K.S. Channer, T.H. Jones // Eur J Endocrinol. – 2006. – Vol. 154. – P. 899–906.

Channer K. Prospective evaluation of the effects of testosterone therapy in hypogonadal men with type 2 diabetes or metabolic syndrome: demographic analysis of TIMES2 study / K. Channer, C. Dumas // Diabetes. Vasc. Dis. Res. – 2007. – Vol. 4. – Р. 164.

Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS) / R. Bhattacharya [et al.] // BMC Endoc. Disord. – 2011. – Vol. 11. – P. 18.

Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip / J. Svatberg, I. Agledahl, T. Sildnes, Y. Figenschan // Int. J. Impot. Res. – 2008. – Vol. 20. – P. 378–387.

Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review / F. Saad, A. Aversa, A.M. Isidori, L.J. Gooren // Curr Diabetes Rev. – 2012. – Vol. 8. – P. 131–143.

Identification of late-onset hypogonadism in middle-aged and elderly men / F.C. Wu, A. Tajar, J.M. Beynon [et al.] // N. Engl. J. Med. – 2010. – Vol. 363. – Р. 123–135.

Androgеns and diabеtic in mеn: Rеsults from thе Third National Hеalth and Nutrition Еxamination Syrvеy (NHANЕS III) / Е. Sеlvin, M. Fеinlеib, L. Zhang [еt al.] // Diabеtеs Carе. – 2007. – Vol. 30. – P. 234–238.

Zhody W. Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction / W. Zhody, E.E. Kamal, Y.J. Ibrahim // Sex. Med. – 2007. – Vol. 4. – P. 797–808.